Article Text

PDF

CC-chemokine ligand 18 is a useful biomarker associated with disease activity in IgG4-related disease
  1. Mitsuhiro Akiyama,
  2. Hidekata Yasuoka,
  3. Keiko Yoshimoto,
  4. Tsutomu Takeuchi
  1. Department of Internal Medicine, Division of Rheumatology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
  1. Correspondence to Dr Mitsuhiro Akiyama, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan; hhhirooo{at}hotmail.com and Dr Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio UniversitySchool of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan; tsutake{at}z5.keio.jp

Statistics from Altmetric.com

IgG4-related disease (IgG4-RD) is a systemic disorder characterised by elevated serum IgG4 levels, tissue infiltration by IgG4+ plasma cells and severe fibrosis.1 2 However, biomarkers for IgG4-RD disease activity are lacking.3 A recent report demonstrated that CC-chemokine ligand 18 (CCL18) was a substantial biomarker for fibrotic diseases.4 Here, we investigated the correlation between serum CCL18 levels and clinical features of patients with IgG4-RD.

Written informed consent was obtained from all patients and healthy controls. Twenty-eight consecutive patients with active, untreated IgG4-RD diagnosed based on the 2011 comprehensive diagnostic criteria5 and 16 healthy controls were enrolled. Diagnosis of IgG4-RD was biopsy proven in 26 patients (93%). Disease activity was assessed using the IgG4-RD responder index (IgG4-RD RI).6 Healthy controls had no autoimmune diseases, atopic diseases or active infections at enrolment. Serum CCL18 levels were measured using a human CCL18/PARC Quantikine ELISA Kit (R&D Systems, Minneapolis, Minnesota, USA).

Characteristics of patients are shown in table 1. The mean age of patients with IgG4-RD and healthy controls was 59.7 and 47.3 years, and the proportion of females were 50% (14/28) and 69% (11/16), respectively.

Table 1

Characteristics of patients with IgG4-related disease

Serum CCL18 levels in patients with IgG4-RD (median 44.5 ng/mL, range 3.6–120.9 ng/mL) were significantly higher than those in healthy controls (median 13.0 ng/mL, range 0.1–63.8 ng/mL; p=0.01) (figure 1A). The number of IgG4-RD patients with above normal levels of serum CCL18 (mean+1.96 SD of the healthy controls: 27.79 ng/mL) was 17 (61%), which was significantly higher than that of healthy controls (n=3, 19%; p=0.01). Of note, serum CCL18 levels were positively correlated with IgG4-RD RI score (ρ=0.54, p<0.005), number of affected organs (ρ=0.56, p<0.005), serum IgG4 level (ρ=0.50, p<0.01) and soluble Interleukin (IL)-2 receptor level (ρ=0.56, p<0.005), but not serum IgE level (ρ=−0.05, p=0.79) or blood eosinophil count (ρ=0.18, p=0.38), suggesting that serum CCL18 level is associated with IgG4-RD disease status rather than allergic condition (figure 1B, C). In line with this observation, serum CCL18 levels were similar between IgG4-RD patients with and without an atopic history (mean 47.8 vs 40.0 ng/mL, p=0.51; figure 1D). There was no statistically significant correlation between specific organ involvement and higher serum CCL18 levels. Serum CCL18 levels significantly decreased after glucocorticoid treatment (44.7 ng/mL vs 12.7 ng/mL, p<0.01; figure 1E) with declining disease activity (IgG4-RD RI: 12 vs 2, p<0.01).

Figure 1

Serum CC-chemokine ligand 18 (CCL18) levels were elevated and correlated with disease activity in IgG4-RD. Serum CCL18 levels (A); correlation between serum CCL18 levels and disease activity (B) and allergic condition (C); correlation between serum CCL18 levels and atopic history (D); and longitudinal analysis of serum CCL18 levels after glucocorticoid treatment (E). Group-wise comparisons were performed using the Mann-Whitney U test. The correlation between serum CCL18 level and clinical parameters including IgG4-RD responder index; number of affected organs; levels of IgG4, sIL-2R, and IgE; and eosinophil count was analysed using Spearman’s correlation coefficient. Differences before and after glucocorticoid treatment were determined using the Wilcoxon rank sum test for paired samples. A two-sided p value <0.05 was considered significant. All statistical analyses were performed using GraphPad Prism V.6.0 (GraphPad, La Jolla, California, USA). GC, glucocorticoid; HC, healthy controls; IgG4-RD, IgG4-related disease; sIL-2R, soluble IL-2 receptor.

Recent reports suggest that M2 macrophages are involved in the process of fibrosis.7 CCL18 is primarily secreted from activated M2 macrophages induced by T helper type 2-associated cytokines such as IL-4 and IL-13,8 and plays a role in the stimulation of collagen production by fibroblasts.9 Importantly, DNA microarray analysis showed that CCL18 was upregulated in IgG4-RD-affected tissues.10 Moreover, CCL18 expression was colocalised with massive infiltration of M2 macrophages and positively correlated with the fibrosis scores at affected IgG4-RD sites.7 Thus, CCL18 secreted by M2 macrophages plays a significant role in the fibrotic process in IgG4-RD.7

Our study has several limitations. For example, serum CCL18 levels after glucocorticoid treatment may be a direct result of the medication rather than being a secondary marker of disease activity like other biomarkers. To eliminate the possible confounding effects of glucocorticoids on the decline in CCL18 levels, further longitudinal studies in patients with relapsing or glucocorticoid-resistant IgG4-RD are required. Such studies can clarify whether a preceding elevation in serum CCL18 level is a predictive indicator for subsequent relapse of IgG4-RD activity in guiding treatment decisions.

In conclusion, our results indicate that CCL18 is a useful biomarker for evaluating not only the disease activity of IgG4-RD, but also patient response to therapy. Our data suggest that CCL18 may be a novel therapeutic target for IgG4-RD.

Acknowledgments

We thank all the patients and healthy individuals who participated in this study. We would like to thank the staff of the Rheumatology Division of Keio University School of Medicine for treating the patients.

References

View Abstract

Footnotes

  • Contributors All authors were involved in the drafting of the article or critical revision of important intellectual content, and all authors approved the final version to be published.

  • Funding This study was supported by an institutional research grant from Keio University and by Mitsubishi Tanabe Pharma Company, Japan.

  • Competing interests MA has received consultancies, speaking fees and honoraria from Asahi Kasei Co, Cure Grades Co, and Eisai Co., and a research grant from Mitsubishi Tanabe Pharma Co. TT has received consulting fees, speaking fees and/or honoraria from Pfizer Japan, Mitsubishi Tanabe Pharma, Eisai, Astellas Pharma and UCB (less than $10 000 each) and Chugai Pharmaceutical, Bristol-Myers K.K, Daiichi Sankyo, AbbVie, Janssen Pharmaceutical K.K, Pfizer Japan, Asahi Kasei Pharma, Takeda Pharmaceutical, AstraZeneca K.K., Eli Lilly Japan K.K, and Novartis Pharma K.K. (more than $10 000 each).

  • Ethics approval Ethics Committee of Keio University School of Medicine.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.